Organogenesis (NASDAQ:ORGO) Stock Price Down 1.6% – Time to Sell?

Organogenesis (NASDAQ:ORGO) shares fell 1.6% during mid-day trading on Friday . The stock traded as low as $2.32 and last traded at $2.39. 1,179,184 shares were traded during mid-day trading, an increase of 51% from the average daily volume of 783,361 shares. The stock had previously closed at $2.43.

Analysts Set New Price Targets

Several analysts recently weighed in on ORGO shares. Truist Financial initiated coverage on Organogenesis in a research report on Thursday, May 28th. They set a “hold” rating and a $3.00 price objective for the company. Wall Street Zen upgraded Organogenesis from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. BTIG Research downgraded Organogenesis from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. UBS Group set a $3.00 target price on shares of Organogenesis in a report on Thursday, May 28th. Finally, Weiss Ratings downgraded shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Organogenesis presently has a consensus rating of “Hold” and an average target price of $5.75.

Organogenesis Stock Down 1.6%

The company has a market capitalization of $307.55 million, a price-to-earnings ratio of -12.58 and a beta of 1.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.53 and a quick ratio of 3.16. The firm’s fifty day moving average price is $2.47 and its 200-day moving average price is $2.88.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.08). The firm had revenue of $37.23 million for the quarter, compared to analyst estimates of $43.26 million. Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%.

Institutional Trading of Organogenesis

A number of hedge funds have recently made changes to their positions in ORGO. First Light Asset Management LLC bought a new stake in shares of Organogenesis during the second quarter worth about $24,804,000. Assenagon Asset Management S.A. raised its holdings in Organogenesis by 14.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after buying an additional 680,392 shares during the last quarter. Deutsche Bank AG boosted its position in Organogenesis by 0.4% during the 4th quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock worth $17,082,000 after buying an additional 13,301 shares during the period. Dimensional Fund Advisors LP grew its holdings in Organogenesis by 5.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock worth $6,851,000 after acquiring an additional 160,026 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Organogenesis by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock worth $9,259,000 after acquiring an additional 62,346 shares during the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.